Moleculin Biotech Net Income
| MBRX Stock | USD 4.14 0.02 0.49% |
As of the 10th of February, Moleculin Biotech secures the Risk Adjusted Performance of (0.15), standard deviation of 6.77, and Mean Deviation of 4.66. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Moleculin Biotech, as well as the relationship between them.
Moleculin Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Moleculin Biotech's valuation are provided below:We have found one hundred twenty available fundamental ratios for Moleculin Biotech, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Moleculin Biotech last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 35.8 M in 2026. Enterprise Value is likely to rise to about (22.7 M) in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -19.6 M | -20.6 M | |
| Net Loss | -14.3 M | -15 M | |
| Net Loss | -19.6 M | -20.6 M | |
| Net Loss | (142.22) | (149.33) | |
| Net Income Per E B T | 0.88 | 0.78 |
Moleculin | Net Income | Build AI portfolio with Moleculin Stock |
The evolution of Net Income for Moleculin Biotech provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Moleculin Biotech compares to historical norms and industry peers.
Latest Moleculin Biotech's Net Income Growth Pattern
Below is the plot of the Net Income of Moleculin Biotech over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Moleculin Biotech financial statement analysis. It represents the amount of money remaining after all of Moleculin Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Moleculin Biotech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (21.76 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Moleculin Net Income Regression Statistics
| Arithmetic Mean | (11,603,603) | |
| Coefficient Of Variation | (88.94) | |
| Mean Deviation | 8,777,330 | |
| Median | (11,876,000) | |
| Standard Deviation | 10,320,104 | |
| Sample Variance | 106.5T | |
| Range | 29M | |
| R-Value | (0.90) | |
| Mean Square Error | 21.6T | |
| R-Squared | 0.81 | |
| Slope | (1,839,220) | |
| Total Sum of Squares | 1704.1T |
Moleculin Net Income History
Other Fundumenentals of Moleculin Biotech
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Moleculin Biotech Net Income component correlations
Moleculin Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Moleculin Biotech is extremely important. It helps to project a fair market value of Moleculin Stock properly, considering its historical fundamentals such as Net Income. Since Moleculin Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moleculin Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moleculin Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. Expected growth trajectory for Moleculin significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Moleculin Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Moleculin Biotech requires distinguishing between market price and book value, where the latter reflects Moleculin's accounting equity. The concept of intrinsic value - what Moleculin Biotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Moleculin Biotech's price substantially above or below its fundamental value.
Understanding that Moleculin Biotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Moleculin Biotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Moleculin Biotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Moleculin Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Moleculin Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Moleculin Biotech.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Moleculin Biotech on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Moleculin Biotech or generate 0.0% return on investment in Moleculin Biotech over 90 days. Moleculin Biotech is related to or competes with Apollomics, Athira Pharma, SeaStar Medical, Lunai Bioworks, Citius Pharmaceuticals, Tharimmune, and Ainos. Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the ... More
Moleculin Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Moleculin Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Moleculin Biotech upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 41.63 | |||
| Value At Risk | (11.73) | |||
| Potential Upside | 9.37 |
Moleculin Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Moleculin Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Moleculin Biotech's standard deviation. In reality, there are many statistical measures that can use Moleculin Biotech historical prices to predict the future Moleculin Biotech's volatility.| Risk Adjusted Performance | (0.15) | |||
| Jensen Alpha | (1.49) | |||
| Total Risk Alpha | (2.06) | |||
| Treynor Ratio | (0.83) |
Moleculin Biotech February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (0.82) | |||
| Mean Deviation | 4.66 | |||
| Coefficient Of Variation | (502.27) | |||
| Standard Deviation | 6.77 | |||
| Variance | 45.78 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (1.49) | |||
| Total Risk Alpha | (2.06) | |||
| Treynor Ratio | (0.83) | |||
| Maximum Drawdown | 41.63 | |||
| Value At Risk | (11.73) | |||
| Potential Upside | 9.37 | |||
| Skewness | (1.02) | |||
| Kurtosis | 3.55 |
Moleculin Biotech Backtested Returns
Moleculin Biotech has Sharpe Ratio of -0.21, which conveys that the firm had a -0.21 % return per unit of risk over the last 3 months. Moleculin Biotech exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Moleculin Biotech's Standard Deviation of 6.77, risk adjusted performance of (0.15), and Mean Deviation of 4.66 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.63, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Moleculin Biotech will likely underperform. At this point, Moleculin Biotech has a negative expected return of -1.48%. Please make sure to verify Moleculin Biotech's information ratio, skewness, as well as the relationship between the Skewness and day typical price , to decide if Moleculin Biotech performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.54 |
Good reverse predictability
Moleculin Biotech has good reverse predictability. Overlapping area represents the amount of predictability between Moleculin Biotech time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Moleculin Biotech price movement. The serial correlation of -0.54 indicates that about 54.0% of current Moleculin Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.54 | |
| Spearman Rank Test | -0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Moleculin Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Moleculin Biotech reported net income of (21.76 Million). This is 106.38% lower than that of the Biotechnology sector and 131.07% lower than that of the Health Care industry. The net income for all United States stocks is 103.81% higher than that of the company.
Moleculin Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moleculin Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moleculin Biotech could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics of similar companies.Moleculin Biotech is currently under evaluation in net income category among its peers.
Moleculin Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Moleculin Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Moleculin Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Moleculin Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Moleculin Biotech that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Moleculin Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moleculin Biotech's value.| Shares | Tower Research Capital Llc | 2025-06-30 | 3.9 K | Stone House Investment Management, Llc | 2025-06-30 | 3.3 K | Newbridge Financial Services Group, Inc. | 2025-06-30 | 2.9 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 926 | Sbi Securities Co Ltd | 2025-06-30 | 746 | Atlantic Union Bankshares Corp | 2025-06-30 | 379 | Barclays Plc | 2025-03-31 | 344 | Bogart Wealth, Llc | 2025-06-30 | 300 | Bank Of America Corp | 2025-06-30 | 146 | Citigroup Inc | 2025-06-30 | 85.3 K | Xtx Topco Ltd | 2025-06-30 | 74.2 K |
Moleculin Fundamentals
| Return On Equity | -5.04 | ||||
| Return On Asset | -0.67 | ||||
| Current Valuation | 6.37 M | ||||
| Shares Outstanding | 49.5 M | ||||
| Shares Owned By Insiders | 2.24 % | ||||
| Shares Owned By Institutions | 4.66 % | ||||
| Number Of Shares Shorted | 358.09 K | ||||
| Price To Earning | (3.81) X | ||||
| Price To Book | 476.20 X | ||||
| EBITDA | (26.52 M) | ||||
| Net Income | (21.76 M) | ||||
| Cash And Equivalents | 58 M | ||||
| Cash Per Share | 2.03 X | ||||
| Total Debt | 478 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (23.86 M) | ||||
| Short Ratio | 2.16 X | ||||
| Earnings Per Share | (3.74) X | ||||
| Target Price | 6.67 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.55 | ||||
| Market Capitalization | 22.47 M | ||||
| Total Asset | 16.93 M | ||||
| Retained Earnings | (153.37 M) | ||||
| Working Capital | (165 K) | ||||
| Current Asset | 28.09 K | ||||
| Current Liabilities | 772.79 K | ||||
| Net Asset | 16.93 M |
About Moleculin Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.